3D Medicines Inc. provided earning guidance for the six months ended June 30, 2023. The board of directors of the Company informed the shareholders of the Company (the "Shareholders") and potential investors that, based on the preliminary review of the Group's unaudited management accounts for the six months ended June 30, 2023, the total revenue of the Group for the six months ended June 30, 2023 is expected to be within the range of RMB 343.8 million to RMB 361.4 million, representing an increase in the range of 66.1% to 74.6% from approximately RMB 207.0 million for the six months ended June 30, 2022. The gross profit of the Group for the six months ended June 30, 2023 is expected to be within the range of RMB 319.4 million to RMB 335.8 million, representing an increase in the range of 66.1% to 74.6% from approximately RMB192.3 million for the six months ended June 30, 2022.

The increase in total revenue and gross profit was mainly due to the increased revenue and the gross profit of product, namely Envafolimab. The gross profit margin of the Company for the six months ended June 30, 2023 is expected to be 92.9%, which is flat compared to approximately 92.9% for the six months ended June 30, 2022.